Showing results (741-750 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|June 19, 2020
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemicMitch Dowsett, Matthew J Ellis, J Michael Dixon, et al.
NPJ Breast Cancer|September 18, 2021
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodiesNina Radosevic-Robin, Pier Selenica, Yingjie Zhu, et al.
NPJ Breast Cancer|August 29, 2025
The association between young age at metastatic breast cancer diagnosis and overall survival in the EMBRACE studyKristen D Brantley, Gregory J Kirkner, Melissa E Hughes, et al.
NPJ Breast Cancer|May 21, 2021
NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumabPatricia A Ganz, Reena S Cecchini, Louis Fehrenbacher, et al.
NPJ Breast Cancer|May 13, 2021
RIPK1 is a negative mediator in Aquaporin 1-driven triple-negative breast carcinoma progression and metastasisZhuming Yin, Wenlin Chen, Jian Yin, et al.
NPJ Breast Cancer|February 13, 2023
Immunotherapy in breast cancer: an overview of current strategies and perspectivesVéronique Debien, Alex De Caluwé, Xiaoxiao Wang, et al.
NPJ Breast Cancer|December 13, 2016
Genetic variation in the insulin, insulin-like growth factor, growth hormone, and leptin pathways in relation to breast cancer in African-American women: the AMBER consortiumEdward A Ruiz-Narváez, Kathryn L Lunetta, Chi-Chen Hong, et al.
NPJ Breast Cancer|February 25, 2017
Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancerWei-Gang Qiu, Alla Polotskaia, Gu Xiao, et al.
NPJ Breast Cancer|September 10, 2022
Immunologically "cold" triple negative breast cancers engraft at a higher rate in patient derived xenograftsVarduhi Petrosyan, Lacey E Dobrolecki, Emily L LaPlante, et al.
NPJ Breast Cancer|February 9, 2021
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancerJulia Foldi, Andrea Silber, Emily Reisenbichler, et al.
Pageof 98